- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03844152
RIGHTWHEY - Responders In Gut HealTh Markers Using Fermented WHEY (RIGHTWHEY)
Investigating the Effect of Fermented Whey Concentrate on Gut Microbial Activity: Does Butyrate Matter?
This 8-week intervention will investigate the effect of daily consumption of a fermented whey concentrate on the short-chain fatty acid profile of faeces in healthy individuals.
This study will help us understand if consumption of fermented foods rich in lactic acid have a beneficial effect on gut health.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The 8-week dietary supplementation trial will investigate the action of exogenous lactic acid consumption on the activity (using short-chain fatty acid) and composition of the gut microbiota.
Participants will be stratified according to their baseline faecal butyrate levels. Therefore volunteers will be asked to provide two faecal samples one week apart. Based on the average absolute level of butyrate in the faecal samples, volunteers will be stratified into either low, moderate or high baseline butyrate levels (detailed in table 1 below). The levels for faecal butyrate for each group are set based on a meta-analysis of 9 human studies of healthy volunteers carried out at the Rowett Institute (n=116; LaBouyer et al, 2016, unpublished). Thresholds were derived from the boundaries of tertiles. Therefore, the moderate butyrate producers represent the middle 33% (see table). Each stratification arm will have a minimum of 17 study volunteers bringing the total to n=51. This has been set to ensure the completion of at least 45 volunteers. To optimise equal gender distribution amongst all study arms a minimum of 5 females and 5 males will be recruited for each arm.
Stratification Butyrate range Low ≤13 mM Moderate butyrate 13 - 20mM High butyrate ≥20mM
Primary and secondary outcomes will be analysed between the low and high butyrate producing groups as well as the overall group effect on everyone.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Aberdeen, United Kingdom, AB25 2ZD
- The Rowett Institute, Human Nutrition Unit
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- i. Men and women aged 18-68 years; BMI ranging from 18-35 kg/m2; measured at the screening visit
Exclusion Criteria:
- i. smokers
- ii. subjects with: diagnosis of diabetes, pregnant, hypertension, renal, hepatic, haematological disease, coronary heart disease or any gastrointestinal disorder
- ii. unsuitable veins for blood sampling;
- iii. inability to speak, read and understand English.
- iv. Use of antibiotics within the last 3 months will automatically exclude volunteers.
- v. Vegans. Fermented whey concentrate, (FWC), is derived from milk (animal product) which excludes potential participants adhering to a vegan diet.
- vi. allergy to any of the following: cow milk, lactose, casein, whey, sucralose, acesulfame K, citric acid, potassium benzoate, fruit flavourings.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Fermented whey concentrate
Volunteers will receive the premixed water and fermented whey in weekly deliveries in 1.5L bottles and a drinking glass with a clear indication of the required 200ml volume.
Participants will be asked to drink 200 ml of the supplemented water twice daily for the active intervention period.
|
The investigated dietary supplement is a form of lacto-fermented whey concentrate (FWC), which has been deproteinised and then diluted (1/20) in sugar-free flavoured water to improve palatability.
The main solute within the lacto-fermented whey is L-(+)-lactic acid (7%), produced through bacterial fermentation of the milk sugar lactose.
The research team will provide non-descriptive bottles of drink to all volunteers.
The flavour of the FWC will be masked by the flavoured water.
In order to assess compliance and minimize an initial treatment effect, a 14 day run-in period during which only flavoured water is to be consumed will be completed by all volunteers.
At the same time, this period will act as a wash-out, as volunteers will be asked to abstain from the use of any dietary supplements during this period and the rest of the study.
The daily energy content of the FWC is 4kcal.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Faecal butyrate concentration - comparing upper and lower tertile of volunteers
Time Frame: Baseline measurement (Visit 1) and end of study (visit 3, 8 weeks later) [Baseline butyrate calculated from the average of two values per individual at Day -7 and Day 0; End of study value is the average from two samples collected at Day 49 and 56
|
Change in relative proportion of butyrate (percentage of total SCFA - sum of propionate, butyrate, acetate, valerate, iso-valerate, iso-butyrate, succinate, lactate mM (millimolar values from gas chromatography) and absolute concentration (mM millimolar) when comparing volunteers as stratified by faecal butyrate levels at start of study.
A comparison will be made between the butyrate concentration-dependent groupings.
|
Baseline measurement (Visit 1) and end of study (visit 3, 8 weeks later) [Baseline butyrate calculated from the average of two values per individual at Day -7 and Day 0; End of study value is the average from two samples collected at Day 49 and 56
|
Faecal butyrate concentration - intervention group effect
Time Frame: Baseline measurement (Visit 1) and end of study (visit 3, 8 weeks later) [Baseline butyrate calculated from the average of two values per individual at Day -7 and Day 0; End of study value is the average from two samples collected at Day 49 and 56
|
Change in relative proportion of butyrate (percentage of total SCFA) and absolute concentration (mM, millimolar) across the total study group
|
Baseline measurement (Visit 1) and end of study (visit 3, 8 weeks later) [Baseline butyrate calculated from the average of two values per individual at Day -7 and Day 0; End of study value is the average from two samples collected at Day 49 and 56
|
Microbiota composition change
Time Frame: Assessed as change between day 0 and day 56
|
Changes in the composition of the microbiota will be based on next-generation sequence analysis of 16S rRNA (ribosomal ribonucleic acid) genes extracted from faecal samples provided by all volunteers
|
Assessed as change between day 0 and day 56
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Gastrointestinal wellness questionnaire
Time Frame: Day 0, 7, 14, 21, 28, 35, 42, 49 and 56
|
Changes in frequency or consistency of bowel movements and gastrointestinal well being will be assessed with a self-administered weekly questionnaire (ranked on a linear likert scale). The questionnaire asks volunteers to rank nausea, bloating, flatulence, abdominal cramps, rumbling, indigestion, fullness/distension and early satiation over the last 24 hours. The scale is scored from -3 being considerably less, -2 moderately less, -1 for slightly less and 0 for as usual. Responses such as slightly more are scored as 1, moderately more as 2 and considerately more as 3. Scores will be aggregated across all categories and compared as a whole to represent general GI wellness changing throughout the intervention. Participants have a blank box to fill in with the number of bowel movements in the last 24hr and are asked to rank them on the Bristol stool scale (0-7, visual guide included in the questionnaire). Scores will be assessed as averages over the control and intervention periods. |
Day 0, 7, 14, 21, 28, 35, 42, 49 and 56
|
Glucose tolerance and insulin sensitivity
Time Frame: Measured on Day 0 and Day 56
|
Comparison of change in response to Oral glucose tolerance test (3 hours) using the total and incremental area under the curve (AUC)for both glucose and insulin concentrations. Both values are measured in arbitrary units and calculated by the standard trapezoid method. Incremental AUC is the baseline corrected output for total AUC. Comparison will be made between group averages at baseline and post-intervention |
Measured on Day 0 and Day 56
|
Health related quality of life questionnaire
Time Frame: scored on Day 0 and 56
|
Change in score in health-related quality of life questionnaire General health is ranked on a scale of excellent, very good, good, fair and poor with scores ranging from 1 - 5 respectively. Volunteers are asked to write the relevant days they have been affected by: physical health, mental health or impaired by poor mental and physical health, or pain over the last 30 days. Participants are asked to respond to the following questions relating to the past 30 days: how many days have they felt sad/blue, worried/tense/anxious, did not have enough rest/sleep and have felt very healthy and full of energy. Each category will be individually compared at baseline and post-intervention. |
scored on Day 0 and 56
|
Small intestinal fermentation
Time Frame: measured on Days 0, 14 and 56
|
Change in Breath test assessment of hydrogen and methane levels (given in ppm - parts per million) and faecal pH (using standard pH meter)
|
measured on Days 0, 14 and 56
|
Faecal pH
Time Frame: measured at day 0 and 56
|
Change in Faecal pH, using standard pH meter - Scale 0-14
|
measured at day 0 and 56
|
Faecal moisture content
Time Frame: measured at day 0 and 56
|
proportion of faeces (in the percentage of total weight) made up of water
|
measured at day 0 and 56
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Karen P Scott, PhD, University of Aberdeen
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 808
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Fermented whey concentrate
-
University College DublinFHI 360Completed
-
Auburn UniversityCompletedSkeletal Muscle
-
University of the Incarnate WordEnrolling by invitation
-
University of LimerickUnknown
-
University of LimerickMarigot Ltd.; Enterprise IrelandCompletedBioavailability of Amino Acids Following Oral Ingestion of Plant-Based Proteins in Young, Healthy MenIreland
-
Norwegian School of Sport SciencesThe Research Council of Norway; Arkansas Children's Hospital Research Institute and other collaboratorsCompletedHealthy | Elderly | YoungNorway
-
Norwegian School of Sport SciencesArkansas Children's Hospital Research Institute; TineCompletedHealthy Participants
-
All India Institute of Medical Sciences, New DelhiCompleted
-
Wageningen University and ResearchCompleted
-
Stolle Milk Biologic InternationalCompletedHIV Infections | CryptosporidiosisUnited States